Research Paper Volume 13, Issue 12 pp 16696—16712
Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma
Figure 11. TNFRSF14 knockdown promotes EC progression by enhancing EMT. (A) Western blot analysis shows TNFRSF14 protein expression in EC cell lines (HEC1B, RL-952, Hec-1B, and Ishikawa). (B) Western blot analysis shows TNFRSF14 protein levels in control and TNFRSF14-shRNA#1- and TNFRSF14-shRNA#2-transfected RL-952 cells. (C–D) Transwell invasion assay and wound healing assay results show the invasiveness and migration ability of control and TNFRSF14-silenced RL-952 cells. (E) EdU incorporation assay results show the proliferation rates of control and TNFRSF14-silenced RL-952 cells. (F) Flow cytometry analysis shows the percentage apoptosis of 5-fluorouracil-treated control and TNFRSF14 knockdown RL-952 cells. (G) Western blot analysis shows expression levels of EMT-associated marker proteins, Vimentin and Snail, in control and TNFRSF14-silenced RL-952 cells.